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LETTER FROM THE CO-CHAIRS
Dear Colleagues,
The Program Planning Committee and an impressive panel of selected speakers warmly invite 
you to Dubrovnik / Croatia! We are pleased and grateful to once again come together for the  
2017 PDA Europe Virus & TSE Safety Forum!
This conference was established in 2001 and, held annually since then, alternates between 
Europe and the U.S. These truly global meetings are organized under the leadership of PDA in 
close cooperation with European regulatory agencies and the U.S. FDA. They provide an over-
view and updates on regulatory expectations and scientific investigations related to virus and 
TSE safety of biotechnology, plasmaderived and cell-derived medicinal products.
As in previous years, virus contamination of raw materials as well as emerging viral threats will 
be discussed. Appropriate risk mitigation strategies consisting of two elements: i.) Testing and 
processing of raw materials and ii.) Virus removal/inactivation capacity of the processes used 
for production of medicinal products will be taken into consideration. The last day of the con-
ference will focus on TSE and how much vCJD or BSE currently pose a threat to the safety of 
medicinal products.  
This PDA Europe Virus & TSE Safety Forum always provides attendees a unique opportunity for 
interactive discussion and benchmarking. Exchange of information between industry and reg-
ulators will improve the understanding and acceptance of new techniques, highlight new and 
emerging risks and explain new regulatory approaches.
Panel Discussions, luncheons, dinners and a networking event will hopefully complete this im-
pressive program and make it into a worthwhile and well-rounded learning experience for you!
We warmly invite you to join us in Dubrovnik, a World Heritage Site on the Adriatic Sea, rich in 
history and culture.
Johannes Blümel, PhD, Paul-Ehrlich-Institut, Chair Thomas R. Kreil, PhD, Shire, Co-Chair
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12 Georg Roessling, PDA Europe
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SCHEDULE AT A GLANCE
pda.org/eu-virus2017
29 May  9:00 – 17:00 The Principles of Viral Safety for  
Biologics and Vaccines
Pre-Conference  
Workshop
30 May
31 May
1 June
 9:00 –  18:30  
 7:30 – 17:00
 9:00 – 13:30
Virus & TSE Safety Forum Conference, Exhibition
For latest information, please visit: pda.org/eu-virus2017
Welcome to Dubrovnik
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PRE-CONFERENCE WORKSHOP 
This workshop will provide an overview of two important viral safety barriers – testing and 
viral clearance approaches. Typically applied testing methods, the benefits and downsides, 
and some product type specific testing strategies will be presented briefly. The frequently 
discussed NGS technology and its use in this field will be explained in a simple way. With this 
background specific applications and testing strategies for critical raw materials, ATMPs, and 
even medical devices using animal/human derived components will be discussed. 
In the second part, important aspects of viral clearance studies like pre-testing, virus assays, 
viral loads, etc., will be presented and critically reviewed. An overview of the viral removal 
or inactivation capacity of typically applied process steps will also be given and discussed 
using case studies. The workshop will consider current best practice including the current 
regulatory requirements.
It is the intention of the workshop to introduce typical testing strategies and typical viral 
clearance approaches. The workshop will give much room for discussions and participants 
are invited to ask questions related to their specific products, their viral safety strategies, or 
any specific technical or regulatory challenges they have. The speaker panel combines long 
term regulatory experience, industry experience and contract testing laboratory experience, 
all to ensure maximal outcome for attendees.
The Principles of Viral Safety 
for Biologics and Vaccines
Panel Discussion 
Virus Safety Requirements of Raw Materials is one of the topics discussed controversially. PDA aims 
to collect feedback here and approach the European Medicines Agency to include these in a Q&A 
of the respective Guidelines.  
If you have questions, feedback or topics you would like to see addressed, please e-mail them to 
programs-europe@pda.org
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Monday, 29 May 2017
9:00 Welcome and Introduction Georg Roessling, PDA Europe
Horst Ruppach, Charles River,  
Workshop Chair
Plenary 1: Virus Safety Testing
9:15 Standard/Compendial Methods Michael Ruffing,    
Boehringer Ingelheim
9:45 Next Generation Sequencing (NGS) Martin Wisher,    
BioReliance
10:15 Coffee Break
10:45 Testing Strategies: Cell Bank Characterization,  
Bulk Harvest Testing, Raw Material Testing including  
Animal/Human Derived Aids used by ATMP Industry
James Gombold,    
Charles River
11:15 Q&A, Discussion
12:00 Lunch Break
Plenary 2: Viral Clearance
13:00 Regulatory Background: ICH, FDA, EMA Regulations and  
their Applicability to Different Products including ATMPs
Johannes Blümel,    
Paul-Ehrlich-Institut
13:30 Practical Aspects of Viral Clearance Studies:  
Viral Quantification Assays, Pre-testing, Virus Spike
Johanna Kindermann,   
Shire
14:00 The Effectiveness of Typically Applied Process Steps:  
Chromatography, Virus Retentive Filtration, Inactivation by low pH, 
Solvent/Detergent, Gamma Irradiation, etc.
Johannes Blümel,    
Paul-Ehrlich-Institut
14:30 Coffee Break
15:00 Case Study: Viral Clearance Studies for Cell Line Derived  
Recombinant Products, Raw Materials, ATMPs, Medical Devices
Horst Ruppach,    
Charles River
15:30 Panel Discussion &  
Day’s Conclusion
Panelists:
All Speakers
US FDA 
Volunteer Attendees
17:00 End of Pre-Conference Workshop
WORKSHOP AGENDA 
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CONFERENCE AGENDA
9 May 2017
Tuesday, 30 May 2017 
9:00 Welcome and Introduction Georg Roessling, PDA Europe
Johannes Blümel, Co-Chair,   
                Paul-Ehrlich-Institut
Thomas R. Kreil, Co-Chair, Shire
Session 1: Regulatory Developments Moderator: Houman Dehghani, Amgen
9:10 Update on European Regulations Johannes Blümel,    
Paul-Ehrlich-Institut
9:40 Convalescent Plasma for Immune Globulins – Viral Safety Issues Dorothy Scott,    
US FDA
10:10 Validation of Virus Reduction at Continuous Processing  Scott Lute,    
US FDA
10:40 Panel Discussion
11:00 Coffee Break, Poster Session & Exhibition
Session 2: Hepatitis E Virus Moderator: Thomas R. Kreil, Shire
The circulation of hepatitis E virus (HEV) as food-borne pathogen has only recently been recognized in industrialized coun-
tries. Infections remain mostly asymptomatic, as evidenced by high seroprevalence rates but low numbers of clinical case 
reports. HEV has, however, also been transmitted by transfusion of labile blood products, and has occasionally been de-
tected in plasma pools for fractionation. It has thus been considered necessary to verify the safety margins of plasma 
products with respect to HEV, as primarily afforded by virus reduction steps embedded into their manufacturing processes.
11:30 Non-enveloped Viruses with a Lipid Envelope:  
Presence in Plasma and ‘Model’ Virus Preparation for  
Virus Reduction Studies
Maria Farcet,    
Shire
12:00 Hepatitis E Virus Stability Determination in Food –  
Achievements and Challenges
Reimar Johne,    
Federal Institute for Risk Assessment
12:30 Development of a Relevant Model Virus System,  
Cutthroat Trout Virus, for Hepatitis E Virus Clearance Studies
Nathan Roth,    
CSL Behring
13:00 Q & A, Discussion
13:30 Lunch Break, Poster Session & Exhibition
Session 3: Viral Risk Mitigation Strategies Moderator: Albrecht Gröner, PathoGuard
Virus contaminations of biotechnology products derived from carefully tested and selected cell banks may arise from virus 
contaminated raw materials as cell culture media and by cross contamination of products. Risk mitigation strategies such 
as appropriate segregation of product intermediates within and between batches and inactivation / removal of adventi-
tious viruses in raw materials will be presented.
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14:30 Industry Approaches to Facility Segregation for Viral Safety Paul W. Barone,  Massachusetts 
Institute of Technology, Consortium on 
Adventitious Agent Contamination in 
Biomanufacturing (CAACB)
15:00 New Quantitative, Risk-based Approach to 
Appropriate Viral Segregation Measures
Kavita Ramalingam Iyer,   
Merck Sharp & Dohme
15:30 Retrospective Evaluation on the Necessity of End of Use Resin Viral 
Clearance Studies - A Multiple Company Collaboration
Konstantin Zöller, 
Novartis Pharma,
BioPhorum Development Group Viral 
Clearance Working Team
16:00 Mitigation of Risk of Viral Contamination of Media using  
Upstream Barrier Methods
Kathryn Martin Remington,   
BioReliance
16:20 Coffee Break, Poster Session & Exhibition
17:00 Minute Virus of Mice - Non-susceptible CHO Cell Line Kevin Kayser,    
Merck KGaA
17:20 Defend Your Bioreactor:  
Using Nanofiltration to Prevent Virus Contamination of  
Cell Culture Processes
Christina Carbrello,   
Merck Group
17:40 Virus Risk Mitigation in Cell Culture Media –  
New Solutions
Anika Manzke,    
Sartorius Stedim Biotech
18:00 Q & A, Discussion
18:30 End of Day 1
19:00 Networking Reception
Wednesday, 31 May 2017 
MORNING SESSION
Interest Group Meeting: Advanced Virus Detection Technologies
- OPEN TO ALL -
Moderators: Arifa Khan, US FDA
Jean-Pol Cassart, GSK 
The Advanced Virus Detection Technologies Interest Group (AVDTIG) is comprised of experts representing industry, aca-
demia, government agencies and regulators who discuss the current thinking and planned efforts regarding application of 
new technologies for virus detection in biologicals. The group’s current focus is on next generation sequencing. The ses-
sion will include brief presentations on the IG history, ongoing activities, and achievements followed by audience partici-
pation for Q & A and discussions on additional topics on advanced virus detection technologies for consideration by the IG. 
7:30 Update on IG Activities 
Open Forum and Discussion, Q&A
8:45 Welcome Coffee
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Session 4: Methods for Virus Detection Moderator: Arifa Khan, US FDA
The “traditional” assays have generally been effective for demonstrating absence of adventitious viruses; however, they may 
not be sufficiently broad to detect viruses that are distant to known viruses or novel viruses. Virus detection by the routinely 
used cell culture and molecular methods, and the advanced next generation sequencing technologies will be presented.
9:00 Update on NGS Efforts for Virus Detection Arifa Khan,    
US FDA
9:30 Performance of Transcriptomic Analysis by NGS  
for the Detection of Viral Infection in Cells
Marc Eloit,    
PathoQuest
10:00 Detection of Different MMV Strains by Cell Culture and PCR Assays, 
and MMV Permissiveness of Cell Lines used in Biotechnology: 
How much do we really know?
Thomas R. Kreil,    
Shire
10:30 Comparing Classical vs New Assays Siemon Ng,    
Sanofi
11:00 Q & A, Discussion
11:30 Lunch Break, Poster Session & Exhibition
Session 5: Virus Filtration Moderator: Martin Wisher, BioReliance
The use of virus filtration in the processing of biological products is considered a robust and well accepted component of 
a virus clearance strategy. This session will provide new data on a number of topics related to the use of this technology 
including virus retention mechanisms, effects on virus reduction factors of different model parvoviruses, effects of pro-
cess fluid properties, processing parameters and depressurization/re-pressurization, development of a new nano-cellulose 
based membrane, and the application of QbD to virus removal by filtration.
13:00 Differential Retention of Animal Parvoviruses during Virus Filtration Thomas Nowak,    
CSL Behring
13:20 Retention Mechanisms in Virus Filtration: 
Membrane Contribution by Size Exclusion and Interactions Between 
Membrane, Viruses and Solutes under Varied Buffer Conditions
Björn Hansmann,    
Sartorius Stedim Biotech
13:40 Understanding Virus Filtration and Designing Viral Clearance 
Studies to Accurately Assess Parvovirus Removal Capability
Daniel Strauss,    
Asahi Kasei
14:00 Demonstration of Effective Control of Viral Filtration Unit 
Operation to Adequately Address the Safety Concern Raised 
by Health Authorities
Dayue Chen,    
Eli Lilly
14:30 Coffee Break, Poster Session & Exhibition
15:00 Multiple, Deliberate Interruptions of a 
Virus Removal Filtration Process – 
Impact on Virus Retention and Throughput
Konstantin Zöller,    
Novartis Pharma
15:20 Nano-cellulose-based Small-size Virus Retentive Filters Albert Mihranyan,    
Uppsala University
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15:40 Application of Quality by Design (QbD) Principles for 
Validation of Virus Removal by Filtration
Morven MacAlister,   
PALL Life Sciences 
16:00 Q & A, Discussion
17:00 End of Day 2  
Thursday, 1 June 2017 
Session 6: Virus Clearance Moderator: Qi Chen, Genentech
Triton X-100 is a widely used detergent for enveloped virus inactivation. Due to environmental concerns of Triton X-100 
degradation product, its use in the EU might be restricted through REACh. In this session, the current status and potential 
impact of the REACh authorization for Triton X-10 on biologics manufacturing in EU, as well as virus inactivation data from 
eco-friendly detergents will be discussed. Another hot topic in biologics manufacturing is continuous processing. Applica-
tion of low pH virus inactivation and virus filtration in continuous processing will be presented.
9:00 Advocacy Efforts in Response to Anticipated REACh Regulation 
on Triton X-100
Marie Murphy,   
 Eli Lilly
9:30 An Alternative “Eco-Friendly” Detergent to Triton X-100 Lenore Norling,    
Genentech
10:00 Continuous Viral Clearance for the Production of mAbs Laura Holtmann,   
INVITE
10:30 Q & A, Discussion
11:00 Coffee Break, Poster Session & Exhibition
Session 7: TSE Safety Moderator: Dorothy Scott, US FDA
Existing and emerging TSEs still present potential risks to safety of biological products. This session provides an update on 
human and animal TSE surveillance, including information about atypical BSE. Measures that reduce TSE risk in manufac-
turing include safe sourcing of raw materials, and use of decontamination methods that are effective against TSE agents. 
Methods for inactivation of prions exist but are often harsh and not always suitable for laboratory or manufacturing environ-
ments. A new chemical method to inactivate prions, as measured by RT-QuIC will be presented and discussed.
11:30 Surveillance (human) Including Appendix Studies, 
and Confirmed MV Case
Robert Will,    
University of Edinburgh
12:00 Inactivation of Prions with Hypochlorous Acid (RT-QuIC) Byron Caughey,    
NIH 
12:30 The Current Risk of Atypical BSE Torsten Seuberlich,   
University of Bern
13:00 Q & A, Closing Panel Discussion
13:30 End of Conference, Farewell Lunch
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Join us and your colleagues to enjoy 
drinks and conversation in a relaxing 
atmosphere.
NETWORKING  
RECEPTION
Tuesday, 30 MAY | 19:00 H
EXHIBITION FLOOR PLAN
PDA Registration Table Top Coffee Station
Conference Room
Terrace →
Poster Session 
Poster Session 
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TO E XHIB IT:
Exhibition and Sponsorship Opportunities are available. PDA meetings and conferences are a great oppor-
tunity for your company to gain on-site exposure in front of highly-qualified, upper-level professionals in the 
pharmaceutical and biopharmaceutical industry. Exhibit at PDA events and let your company’s products or 
services become a valuable tool or resource for our attendees.
A basic exhibition package for this event is priced 1.895 Euro net (table-top). Sponsorship Packages are 
available, for more information please contact expo-europe@pda.org
  If this form is an update to a previously submitted form, please check here.
Mr. Ms. Dr. Nonmember
I want to become a PDA Member.  
Please send me a subscription form
Job Title *
Mailing Address
  Substituting for
(Ch e ck only i f  you are subs t i tut ing for a pre v iously e nrolle d colleag ue; a nonme mb e r subs t i tut ing for me mb e r mus t pay t h e me mb e r ship fe e.)
* This information will be published in the conference attendee list. Should you not wish us to publish these details, please contact us.
1 Your Contact Information
PDA Member
Name (Last, First, MI) *
ID Number
Country Email *
FaxBusiness Phone
Company* Department
City Postal Code
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INFORMATION
V E N U E
Sheraton Dubrovnik Riviera Hotel
Šetalište Dr. Franje Tudmana 17  
Srebreno 
Mlini, 20207 
Dubrovnik, Croatia 
Tel: +385 20 601 500 
www.sheratondubrovnikriviera.com
Housing at the selected hotel will be in high demand, so 
we strongly recommend making your reservations early.
CO NTAC T I N FO R M ATI O N
Conference Inquiries
Melanie Decker
Director Events & Exhibitions
decker@pda.org
Conference Program Inquiries
Sylvia Becker
programs-europe@pda.org
Registration Customer Care
Tel: +49 30 4365508-10
registration-europe@pda.org
Education Program Inquiries
Elke von Laufenberg
training-europe@pda.org
Exhibition/Sponsorship Inquiries 
Nadjeschda Gomez-Stahl
expo-europe@pda.org
G E N E R A L A D D R E S S
PDA Europe gGmbH
Am Borsigturm 60
13507 Berlin, Germany
Tel: +49 30 4365508-0
Fax: +49 30 4365508-66  
CO N F E R E N C E R EG I S TR ATI O N H O U R S
Monday, 29 May: 7:30 - 10:00
Tuesday, 30 May: 7:30 - 10:00
S PEC I A L R EQU I R E M E NT S
If you require special accommodations to fully par- 
ticipate, please attach a written description of your 
needs with your registration form. Specific questions can 
be directed to registration-europe@pda.org.
D I R EC TI O N S
© Google  For directions click on the picture, scan the  
QR-code or go to https://goo.gl/maps/be5C8pHkHcx
Special offer: Discounted travel with Lufthansa Group Airlines 
Lufthansa Group Par tner Airlines of fer a comprehensive global 
route network linking major cities around the world. We offer spe-
cial prices and conditions to par ticipants, visitors, exhibitors, in-
vited guests as well as employees of the Contracting par tner and 
their travel companions. To make a reser vation, please click on 
www.lh.com/event-flight-booking and enter the access code 
DEZJPRH in the "Access to Your Special Lufthansa Offer" area. This 
will open an online booking platform that will automatically calcu-
late the discount offered or provide you with an even better offer if 
another promotional fare is available.
NOTE: Pop-ups must be enabled otherwise the booking platform 
window will not open. 
These promotional fares are also available through your IATA / ARC 
travel agent. Travel agents can obtain ticketing instructions by send-
ing an email to lufthansa.mobility@dlh.de and providing the 
access code as a reference.
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Virus & TSE Safety Forum
30 May – 1 June 2017 | Dubrovnik | Croatia
3 WAYS 
TO REGISTER
ONLINE:  pda.org/eu-virus2017
FAX: +49 30 4365508-66
EMAIL: registration-europe@pda.org       
1
2
3
  If this form is an update to a previously submitted form, please check here.
Mr. Ms. Dr. Nonmember
I want to become a PDA Member.  
Please send me a subscription form
Job Title *
Mailing Address
  Substituting for
(Ch e ck only i f  you are subs t i tut ing for a pre v iously e nrolle d colleag ue; a nonme mb e r subs t i tut ing for me mb e r mus t pay t h e me mb e r ship fe e.)
* This information will be published in the conference attendee list. Should you not wish us to publish these details, please contact us.
1 Your Contact Information
PDA Member
Name (Last, First, MI) *
ID Number
Country Email *
FaxBusiness Phone
Company* Department
City Postal Code
 CONFIRMATION: Transmitting your filled-in registration form constitutes a binding application for the specific event. PDA Europe will send you a confirmation including payment details. A legally binding contract is concluded 
once PDA Europe has sent a written invoice by mail to you. A letter of confirmation will be sent to you within one week once payment has been received. You must have this written confirmation to be considered enrolled for 
this PDA event. PDA Europe reserves the right to deny access to anyone unable to provide written confirmation that all dues have been fully settled. SUBSTITUTIONS: If you are unable to attend, substitutions are welcome and can 
be made at any time, including on site at the prevailing rate. If you are registering as a substitute attendee, please indicate this on the registration form. Changes are free of charge until 2 weeks prior to the start of the event. After 
this two-weeks period, there will be a charge of € 100 excl. VAT per name change. REFUNDS: Refund requests must be sent to PDA Europe.  If your written request is received on or before 2 April 2017 you will receive a full refund 
minus a 150 € excl. VAT handling fee. After that time, no refund or credit requests will be approved. If you are an unpaid registrant and do not attend the event, you are responsible for paying the registration fee. On-site registrants are 
not guaranteed to receive conference materials until all advanced registered attendees receive them. PDA Europe works PCI-Compliant. EVENT CANCELLATION: PDA reserves the right to modify the material or speakers/instructors 
without notice, or to cancel an event. If an event must be canceled, registrants will be notified by PDA as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to 
cancellation. For more details, contact PDA at registration-europe@pda.org or fax to +49 30 4365508-66. DOCUMENTATION: With your signature you give complete picture usage right to PDA and allow to film your exhibition 
space and intervention in the event, including the recording of your presentation for video purposes (with your slides, voice and image). This right extends also to the use of the resulting images in film documentation for webinars 
and similar items produced by PDA.
  Discount for Exhibiting Companies  Please mark here if your company is an exhibitor to 
this event and you will receive the conference ticket at the special price of 995 Euro per ticket. 
No further discounts are applicable with this option (as PDA Membership Discount or Group 
Ticket discount). This special rate does not include one-year PDA membership.
PDA Europe VAT I.D.:  DE254459362
3 Payment Options
Billing  
Address:
  Same as contact information address above. If not, please send 
your billing address to: registration-europe@pda.org
Date                                                                                    Mandatory Signature 
  By Credit Card
  American Express   MasterCard   VISA
For your credit card information safety:
Please send your details by fax only (+49 30 4365508-66) or register online.
  By Bank Transfer 
Beneficiary: PDA Europe gGmbH
IBAN: DE73 1007 0024 0922 8735 00    
BIC (SWIFT-Code): DEUTDEDBBER
Bank Address: Deutsche Bank, Welfenallee 3-7, D-13465 Berlin, Germany
  By Purchase Order   Purchase Order Number
 
Group Registration Discount  Register 5 colleagues for the conference at the same time 
and receive the 5th registration free. For more information on group discounts please 
contact us at registration-europe@pda.org. Other discounts cannot be applied.
The fee includes course documentation as well as mid-session refreshments and lunch. 
Excellent networking opportunities with snacks and drinks will be given. The fee does not 
include the hotel accommodation. PDA Europe has secured a limited number of rooms at a 
special group rate.
Information about Visa Matters • All registrations which will involve visa matters will have to be submitted to PDA EU four weeks prior to the start of the event at the latest. For later registrations, PDA Europe will be unable to assist participants in any visa affairs.
• All costs incurring in connection with visa affairs shall be borne by registrants. (This applies in particular to costs for sub-
mitting documents by courier.)
• Potential participants must be clients of UPS shipping agency and submit their UPS customer reference number to PDA EU 
(together with their registration).
Your Company 
VAT I.D.:
This number starts by your country code with two characters 
(example: PDA Europe’s country code starts with: DE | followed by the number)
2 Registration
All fees given in Euro and excluding VAT (25 %)
Conference (30 May–1 June) net
PDA Member  1795
Nonmember**  2095
Govern./Health Authority/Academic**        *Early Bird  800 €  900
  Poster Presenter please mark here (written approval required, conference fee applies)
Pre-Conference Workshop (29 May)
The Principles o Viral Safety fo Biologics and Vaccines
All Participants   795
For contact at PDA Europe
registration-europe@pda.org
**Registration fee includes a one-year PDA membership if no further special discount 
is granted. If you do not wish to join PDA and receive the benefits of membership, please 
check here (same rate applies). 
Organizer: PDA Europe, Am Borsigturm 60, 13507 Berlin, Germany
This PDF-file provides an automatic 
fill-in function. Your signature, 
however, is needed in writing.
HEADERHEADLINE
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Mitigate raw material virus contamination risks with our new virus media filter. Eliminate 
cell growth concerns with Flexsafe® bags. Rely on proven stirred-tank design enhanced with 
single-use biomass measurement. Benefit from robust single-use clarification for up to 
2000 L high performance fed-batch processes.    www.connect-upstream.com
Connect Upstream for Robust Production
